{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:51:02Z","timestamp":1793163062914,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["HI18C0016"],"award-info":[{"award-number":["HI18C0016"]}]},{"name":"Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["HU22C0031"],"award-info":[{"award-number":["HU22C0031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:sup>18<\/jats:sup>F-FP-CIT is a high-resolution imaging marker of nigrostriatal neuronal integrity, differentiating Parkinsonism with loss of dopaminergic terminals (presynaptic Parkinsonian syndrome [PS]) from Parkinsonism without nigrostriatal degeneration (non-PS). We assessed the diagnostic accuracy of <jats:sup>18<\/jats:sup>F-FP-CIT PET in patients with clinically uncertain PS (CUPS) at the first visit. Among the 272 patients who underwent <jats:sup>18<\/jats:sup>F-FP-CIT PET imaging at the first visit between September 2008 and July 2012, 111 had CUPS (age, 62.6\u2009\u00b1\u200910.5 y; male:female, 45:66; symptom duration, 13.1\u2009\u00b1\u20098.8\u00a0months). Uncertainty criteria included only one of the three cardinal signs of Parkinsonism, two signs without bradykinesia, or atypical signs. The baseline clinical and <jats:sup>18<\/jats:sup>F-FP-CIT PET imaging diagnostic accuracy was compared with the accuracy of clinical diagnosis after\u2009&gt;\u20092-year follow-up. Nuclear medicine physicians assessed the <jats:sup>18<\/jats:sup>F-FP-CIT PET images visually. Focal dopamine transporter binding deficit in the posterior putamen was considered PS. Bilateral symmetric striatum without focal deficit, suggesting normal <jats:sup>18<\/jats:sup>F-FP-CIT PET, and focal deficits elsewhere in the striatum suggesting vascular Parkinsonism were considered non-PS. Seventy-nine patients had PS, and 32 did not. Baseline clinical diagnosis included PS in 45 patients, non-PS in 24, and inconclusive in 42. Among patients in whom initial clinical diagnosis (PS or non-PS) was possible, the sensitivity, specificity, and accuracy of the baseline clinical and <jats:sup>18<\/jats:sup>F-FP-CIT PET imaging diagnoses were 54.4, 50.0, and 53.2%, and 98.7, 100, and 99.1%, respectively. The respective positive and negative predictive values were 95.6 and 66.7%, and 100 and 97.0%. Among those with initially inconclusive diagnosis, 64.2% were eventually diagnosed with PS while 35.7% were diagnosed with non-PS. The final clinical diagnosis of these patients all matched those made by <jats:sup>18<\/jats:sup>F-FP-CIT PET imaging, except in one patient with scan without evidence of dopaminergic deficit (SWEDD). <jats:sup>18<\/jats:sup>F-FP-CIT PET diagnosis was more accurate than clinical diagnosis, reducing the false-negative and inconclusive clinical diagnosis rates at baseline in patients with CUPS.<\/jats:p>","DOI":"10.1038\/s41598-023-42135-9","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T11:02:53Z","timestamp":1694516573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnostic accuracy of 18F-FP-CIT PET for clinically uncertain Parkinsonian syndrome"],"prefix":"10.1038","volume":"13","author":[{"given":"Minyoung","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsu S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ju","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"42135_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. Parkinson\u2019s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368\u2013376 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"42135_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mds.10559","volume":"18","author":"MJ Mart\u00cc","year":"2003","unstructured":"Mart\u00cc, M. J., Tolosa, E. & Campdelacreu, J. Clinical overview of the synucleinopathies. Mov. Disord. 18, 21\u201327 (2003).","journal-title":"Mov. Disord."},{"key":"42135_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"42135_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"42135_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnmt.112.111617","volume":"40","author":"E Park","year":"2012","unstructured":"Park, E. A new era of clinical dopamine transporter imaging using 123I-FP-CIT. J. Nucl. Med. Technol. 40, 222\u2013228 (2012).","journal-title":"J. Nucl. Med. Technol."},{"key":"42135_CR6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli, S. et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur. J. Nucl. Med. Mol. Imaging 47, 1885\u20131912 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"42135_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer, W. & Przedborski, S. Parkinson\u2019s disease: Mechanisms and models. Neuron 39, 889\u2013909 (2003).","journal-title":"Neuron"},{"key":"42135_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0165-6147(93)90029-J","volume":"14","author":"B Giros","year":"1993","unstructured":"Giros, B. & Caron, M. G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14, 43\u201349 (1993).","journal-title":"Trends Pharmacol. Sci."},{"key":"42135_CR9","unstructured":"FDA approved drug products. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022454."},{"key":"42135_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2967\/jnumed.111.095224","volume":"53","author":"M Oh","year":"2012","unstructured":"Oh, M. et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J. Nucl. Med. 53, 399\u2013406 (2012).","journal-title":"J. Nucl. Med."},{"key":"42135_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-94040-8","volume":"11","author":"M Oh","year":"2021","unstructured":"Oh, M. et al. Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Sci. Rep. 11, 1\u20138 (2021).","journal-title":"Sci. Rep."},{"key":"42135_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaneurol.2016.3243","volume":"73","author":"S Han","year":"2016","unstructured":"Han, S. et al. Subregional pattern of striatal dopamine transporter loss on 18F FP-CIT positron emission tomography in patients with pure akinesia with gait freezing. JAMA Neurol. 73, 1477\u20131484 (2016).","journal-title":"JAMA Neurol."},{"key":"42135_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/mds.20112","volume":"19","author":"AM Catafau","year":"2004","unstructured":"Catafau, A. M. & Tolosa, E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov. Disord. 19, 1175\u20131182 (2004).","journal-title":"Mov. Disord."},{"key":"42135_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.nucmedbio.2007.02.007","volume":"34","author":"SJ Lee","year":"2007","unstructured":"Lee, S. J. et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nucl. Med. Biol. 34, 345\u2013351 (2007).","journal-title":"Nucl. Med. Biol."},{"key":"42135_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13139-014-0286-0","volume":"48","author":"M Seo","year":"2014","unstructured":"Seo, M. et al. The effect of SSRIs on the binding of (18)F-FP-CIT in Parkinson patients: A retrospective case control study. Nucl. Med. Mol. Imaging 48, 287\u2013294 (2014).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"42135_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00259-015-3191-6","volume":"43","author":"HW Kim","year":"2016","unstructured":"Kim, H. W. et al. Different loss of dopamine transporter according to subtype of multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging 43, 517\u2013525 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"42135_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.22108","volume":"24","author":"VL Marshall","year":"2009","unstructured":"Marshall, V. L. et al. Parkinson\u2019s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov. Disord. 24, 500\u2013508 (2009).","journal-title":"Mov. Disord."},{"key":"42135_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ene.12022","volume":"20","author":"A Berardelli","year":"2013","unstructured":"Berardelli, A. et al. EFNS\/MDS-ES\/ENS [corrected] recommendations for the diagnosis of Parkinson\u2019s disease. Eur. J. Neurol. 20, 16\u201334 (2013).","journal-title":"Eur. J. Neurol."},{"key":"42135_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S0317167100031814","volume":"18","author":"A Rajput","year":"1991","unstructured":"Rajput, A., Rozdilsky, B. & Rajput, A. Accuracy of clinical diagnosis in parkinsonism\u2014A prospective study. Can. J. Neurol. Sci. 18, 275\u2013278 (1991).","journal-title":"Can. J. Neurol. Sci."},{"key":"42135_CR20","first-page":"S111","volume":"29","author":"J Joutsa","year":"2014","unstructured":"Joutsa, J., Gardberg, M., Roytta, M. & Kaasinen, V. Diagnostic accuracy of Parkinsonism syndromes by general neurologists. Mov. Disord. 29, S111\u2013S111 (2014).","journal-title":"Mov. Disord."},{"key":"42135_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00259-008-0777-2","volume":"35","author":"K Van Laere","year":"2008","unstructured":"Van Laere, K. et al. The cost effectiveness of 123 I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur. J. Nucl. Med. Mol. Imaging 35, 1367\u20131376 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"42135_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/mds.22278","volume":"23","author":"A Antonini","year":"2008","unstructured":"Antonini, A. et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson\u2019s disease in Italy. Mov. Disord. 23, 2202\u20132209 (2008).","journal-title":"Mov. Disord."},{"key":"42135_CR23","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1212\/WNL.61.6_suppl_3.S43","volume":"61","author":"K Marek","year":"2003","unstructured":"Marek, K., Jennings, D. & Seibyl, J. Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa. Neurology 61, S43\u2013S48 (2003).","journal-title":"Neurology"},{"key":"42135_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJM200503313521324","volume":"352","author":"JL Walton-Hadlock","year":"2005","unstructured":"Walton-Hadlock, J. L. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 352, 1386 (2005).","journal-title":"N. Engl. J. Med."},{"key":"42135_CR25","first-page":"S143","volume-title":"Movement Disorders","author":"D Jennings","year":"2006","unstructured":"Jennings, D., Tabamo, R., Seibyl, J. & Marek, K. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [1231] beta-CIT and SPECT imaging. In Movement Disorders S143\u2013S144 (Wiley, 2006)."},{"key":"42135_CR26","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"PS Group","year":"2002","unstructured":"Group, P. S. & Group, P. S. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama 287, 1653\u20131661 (2002).","journal-title":"Jama"},{"key":"42135_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/mds.10482","volume":"18","author":"HT Benamer","year":"2003","unstructured":"Benamer, H. T. et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov. Disord. 18, 977\u2013984 (2003).","journal-title":"Mov. Disord."},{"key":"42135_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek, K. et al. The Parkinson\u2019s progression markers initiative (PPMI)\u2013establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460\u20131477 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"42135_CR29","doi-asserted-by":"publisher","first-page":"e0246881","DOI":"10.1371\/journal.pone.0246881","volume":"16","author":"JW Lee","year":"2021","unstructured":"Lee, J. W., Song, Y. S., Kim, H., Ku, B. D. & Lee, W. W. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson\u2019s disease: Analysis of the PPMI data. PLoS ONE 16, e0246881 (2021).","journal-title":"PLoS ONE"},{"key":"42135_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/01.mnm.0000243374.11260.5b","volume":"27","author":"VL Marshall","year":"2006","unstructured":"Marshall, V. L., Patterson, J., Hadley, D. M., Grosset, K. A. & Grosset, D. G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl. Med. Commun. 27, 933\u2013937 (2006).","journal-title":"Nucl. Med. Commun."},{"key":"42135_CR31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.0000000000000424","volume":"82","author":"K Marek","year":"2014","unstructured":"Marek, K. et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82, 1791\u20131797 (2014).","journal-title":"Neurology"},{"key":"42135_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25103","volume":"82","author":"V Kaasinen","year":"2017","unstructured":"Kaasinen, V. & Vahlberg, T. Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Ann. Neurol. 82, 873\u2013882 (2017).","journal-title":"Ann. Neurol."},{"key":"42135_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13139-017-0481-x","volume":"51","author":"C Sung","year":"2017","unstructured":"Sung, C. et al. Longitudinal decline of striatal subregional [18 F] FP-CIT uptake in Parkinson\u2019s disease. Nucl. Med. Mol. Imaging 51, 304\u2013313 (2017).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"42135_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12149-020-01561-9","volume":"35","author":"HJ Son","year":"2021","unstructured":"Son, H. J. et al. Test\u2013retest reproducibility of dopamine transporter density measured with [18 F] FP-CIT PET in patients with essential tremor and Parkinson\u2019s disease. Ann. Nucl. Med. 35, 299\u2013306 (2021).","journal-title":"Ann. Nucl. Med."},{"key":"42135_CR35","doi-asserted-by":"publisher","first-page":"e22032","DOI":"10.1002\/syn.22032","volume":"72","author":"I Lee","year":"2018","unstructured":"Lee, I. et al. Head-to-head comparison of 18F-FP-CIT and 123I-FP-CIT for dopamine transporter imaging in patients with Parkinson\u2019s disease: A preliminary study. Synapse 72, e22032 (2018).","journal-title":"Synapse"},{"key":"42135_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","volume":"15","author":"HT Benamer","year":"2000","unstructured":"Benamer, H. T. et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord. 15, 503\u2013510 (2000).","journal-title":"Mov. Disord."},{"key":"42135_CR37","unstructured":"Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients (FPCIT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00468078."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42135-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T11:20:31Z","timestamp":1700479231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42135-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42135"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42135-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"2 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15069"}}